Clinical Summary of U.S. Preventive Services Task Force Recommendation
|Recommendation||Do not use prostate-specific antigen (PSA)-based screening for prostate cancer.
Contemporary recommendations for prostate cancer screening all incorporate the measurement of serum PSA levels; other methods of detection, such as digital rectal examination or ultrasonography, may be included.
Management strategies for localized prostate cancer include watchful waiting, active surveillance, surgery, and radiation therapy.
|Balance of harms and benefits|
The reduction in prostate cancer mortality 10 to 14 years after PSA-based screening is, at most, very small, even for men in the optimal age range of 55 to 69 years.
|Relevant USPSTF Recommendations||
Recommendations on screening for other types of cancer can be found at http://www.uspreventiveservicestaskforce.org.
For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org.
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
AHRQ Publication No. 12-05160-EF-3
Current as of May 2012
U.S. Preventive Services Task Force. Screening for Prostate Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 12-05160-EF-3. May 2012. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatecanfinalsum.htm